Graft Versus Host Disease Market: Growth & Forecasts, 2032

Graft Versus Host Disease (GVHD) Market – By Disease Type (aGVDH, cGVDH), Treatment Type (Monoclonal Antibodies, mTOR Inhibitors, Immunosuppressants, Corticosteroids), Age Group, Route of Administration, Distribution Channel – Global Forecast 2024 – 2032

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology &amp; Scope

1.1&nbsp;&nbsp;&nbsp; Market scope &amp; definitions

1.2&nbsp;&nbsp;&nbsp; Research design

1.2.1&nbsp;&nbsp;&nbsp; Research approach

1.2.2&nbsp;&nbsp;&nbsp; Data collection methods

1.3&nbsp;&nbsp;&nbsp; Base estimates &amp; calculations

1.3.1&nbsp;&nbsp;&nbsp; Base year calculation

1.3.2&nbsp;&nbsp;&nbsp; Key trends for market estimation

1.4&nbsp;&nbsp;&nbsp; Forecast model

1.5&nbsp;&nbsp;&nbsp; Primary research and validation

1.5.1&nbsp;&nbsp;&nbsp; Primary sources

1.5.2&nbsp;&nbsp;&nbsp; Data mining sources

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Industry 3600&nbsp;synopsis

Chapter 3&nbsp;&nbsp;&nbsp;Industry Insights

3.1&nbsp;&nbsp;&nbsp; Industry ecosystem analysis

3.2&nbsp;&nbsp;&nbsp; Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp; Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp; Increasing prevalence of hematological disorders

3.2.1.2&nbsp;&nbsp;&nbsp; Advancements in transplantation techniques

3.2.1.3&nbsp;&nbsp;&nbsp; Rising investments in research and development

3.2.1.4&nbsp;&nbsp;&nbsp; Growing pipeline of therapeutic agents

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls &amp; challenges

3.2.2.1&nbsp;&nbsp;&nbsp; High treatment cost

3.2.2.2&nbsp;&nbsp;&nbsp; Stringent regulatory challenges

3.2.2.3&nbsp;&nbsp;&nbsp; Risk of complications and relapse

3.3&nbsp;&nbsp;&nbsp; Growth potential analysis

3.4&nbsp;&nbsp;&nbsp; Pipeline analysis

3.5&nbsp;&nbsp;&nbsp; Regulatory landscape

3.6&nbsp;&nbsp;&nbsp; Porter&rsquo;s analysis

3.7&nbsp;&nbsp;&nbsp; PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2023

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company matrix analysis

4.3&nbsp;&nbsp;&nbsp; Competitive analysis of major market players

4.4&nbsp;&nbsp;&nbsp; Competitive positioning matrix

4.5&nbsp;&nbsp;&nbsp; Strategic dashboard

Chapter 5&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Disease Type, 2021 - 2032 ($ Million)

5.1&nbsp;&nbsp;&nbsp; Key trends

5.2&nbsp;&nbsp;&nbsp; Acute graft versus host disease (aGVDH)

5.3&nbsp;&nbsp;&nbsp; Chronic graft versus host disease (cGVDH)

Chapter 6&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Million)

6.1&nbsp;&nbsp;&nbsp; Key trends

6.2&nbsp;&nbsp;&nbsp; Monoclonal antibodies

6.3&nbsp;&nbsp;&nbsp; mTOR inhibitors

6.4&nbsp;&nbsp;&nbsp; Tyrosine kinase inhibitors

6.5&nbsp;&nbsp;&nbsp; Immunosuppressants

6.6&nbsp;&nbsp;&nbsp; Corticosteroids

6.7&nbsp;&nbsp;&nbsp; Other treatment types

Chapter 7&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Age Group, 2021 - 2032 ($ Million)

7.1&nbsp;&nbsp;&nbsp; Key trends

7.2&nbsp;&nbsp;&nbsp; &lt;20 years

7.3&nbsp;&nbsp;&nbsp; 21-50 years

7.4&nbsp;&nbsp;&nbsp; 51 years and above

Chapter 8&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Million)

8.1&nbsp;&nbsp;&nbsp; Key trends

8.2&nbsp;&nbsp;&nbsp; Oral

8.3&nbsp;&nbsp;&nbsp; Intravenous

8.4&nbsp;&nbsp;&nbsp; Topical

Chapter 9&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Million)

9.1&nbsp;&nbsp;&nbsp; Key trends

9.2&nbsp;&nbsp;&nbsp; Hospital pharmacies

9.3&nbsp;&nbsp;&nbsp; Retail pharmacies

9.4&nbsp;&nbsp;&nbsp; Online pharmacies

Chapter 10&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Region, 2021 - 2032 ($ Million)

10.1&nbsp;&nbsp;&nbsp; Key trends, by region

10.2&nbsp;&nbsp;&nbsp; North America

10.2.1&nbsp;&nbsp;&nbsp;U.S.

10.2.2&nbsp;&nbsp;&nbsp;Canada

10.3&nbsp;&nbsp;&nbsp; Europe

10.3.1&nbsp;&nbsp;&nbsp;Germany

10.3.2&nbsp;&nbsp;&nbsp;UK

10.3.3&nbsp;&nbsp;&nbsp;France

10.3.4&nbsp;&nbsp;&nbsp;Spain

10.3.5&nbsp;&nbsp;&nbsp;Italy

10.3.6&nbsp;&nbsp;&nbsp;Rest of Europe

10.4&nbsp;&nbsp;&nbsp; Asia Pacific

10.4.1&nbsp;&nbsp;&nbsp;Japan

10.4.2&nbsp;&nbsp;&nbsp;China

10.4.3&nbsp;&nbsp;&nbsp;India

10.4.4&nbsp;&nbsp;&nbsp;Australia

10.4.5&nbsp;&nbsp;&nbsp;Rest of Asia Pacific

10.5&nbsp;&nbsp;&nbsp; Latin America

10.5.1&nbsp;&nbsp;&nbsp;Brazil

10.5.2&nbsp;&nbsp;&nbsp;Mexico

10.5.3&nbsp;&nbsp;&nbsp;Rest of Latin America

10.6&nbsp;&nbsp;&nbsp; Middle East and Africa

10.6.1&nbsp;&nbsp;&nbsp;South Africa

10.6.2&nbsp;&nbsp;&nbsp;Saudi Arabia

10.6.3&nbsp;&nbsp;&nbsp;Rest of Middle East and Africa

Chapter 11&nbsp;&nbsp;&nbsp;Company Profiles

11.1&nbsp;&nbsp;&nbsp; Astellas Pharma Inc.

11.2&nbsp;&nbsp;&nbsp; Bristol Myers Squibb

11.3&nbsp;&nbsp;&nbsp; ElsaLys Biotech SA

11.4&nbsp;&nbsp;&nbsp; Incyte Corporation

11.5&nbsp;&nbsp;&nbsp; Johnson &amp; Johnson Services, Inc.

11.6&nbsp;&nbsp;&nbsp; Kiadis Pharma

11.7&nbsp;&nbsp;&nbsp; Mallinckrodt Pharmaceuticals

11.8&nbsp;&nbsp;&nbsp; Merck &amp; Co., Inc.

11.9&nbsp;&nbsp;&nbsp; Mesoblast Ltd

11.10&nbsp;&nbsp;&nbsp; Neovii Pharmaceuticals AG

11.11&nbsp;&nbsp;&nbsp; Novartis AG

11.12&nbsp;&nbsp;&nbsp; Pfizer Inc.

11.13&nbsp;&nbsp;&nbsp; Sanofi

11.14&nbsp;&nbsp;&nbsp; Soligenix 
&nbsp;

Graft Versus Host Disease GVHD Market

Get a free sample of this report